Enhanced Stat3 activity has been reported in established endocrine-resistant breast cancer cell models compared to endocrine-sensitive cells [42], leading to the testing of several Stat3 inhibitors in cell line and PDX models of endocrine-resistant and sensitive breast cancer [43, 44]. This evidence concerns the gene STAT3 and breast cancer.